Clongen Laboratories, LLC.

Click here for Complete Press Release

 GERMANTOWN, Md., Nov. 15, 2011 /PRNewswire/ -- Since its inception in 1999, Clongen Laboratories, a CLIA licensed facility with a Maryland Clinical Laboratory license, has focused on improving human health by refining diagnostic tests for infectious diseases and providing contract research services for pharmaceutical, biotechnology, government, and academic institutions.

The advanced molecular diagnostics technology Clongen Laboratories uses in their Clinical Diagnostics Division offers a powerful tool in the screening of a wide range of infectious diseases. This allows healthcare practitioners to better diagnose and treat their patients.  One of the main areas of focus in the Clinical Diagnostics Division is tick borne illness testing; however, Clongen Laboratories also offers a large number of other assays, some not offered anywhere else in the US.  The technology platform Clongen Laboratories uses in the Clinical Diagnostics Division is Real Time PCR.  According to Ahmed Kilani, PhD, founder and director of Clongen Labs, this platform allows Clongen Laboratories to rapidly detect infectious agents in clinical samples at very low copy numbers.  The clinician receives laboratory test results in less than a week from the time of sample receipt.  This quick turnaround offers physicians the opportunity to manage clinical cases without delay.

Clongen Laboratories contract research services are performed under GLP and GMP conditions and encompass a wide range of assays available to pharmaceutical, biotechnology, government and academic institutions.  Services include sterility testing, Mycoplasma detection and elimination, Endotoxin testing and removal, and many others.  In recent years, due to the increased risk of bio-warfare agents, Clongen Laboratories developed rapid real time PCR based assays for the detection of all Bio-warfare select agents listed by the Centers for Disease Control and Prevention (CDC).  The contract research division has grown over the years and now covers a large number of established assays; many are required for lot release of biological and pharmaceutical products.  

The company has been enjoying steady growth and will soon obtain licensure in five additional states.  In addition, Clongen Laboratories is establishing satellite facilities in several other states. According to Dr. Kilani, the mission of Clongen Laboratories, which is to promote improved health through better diagnostic testing and research, has remained consistent since the laboratory was established.

Clongen Laboratories began with less than 10 assay offerings.  Today, the clinical diagnostics division offers more than 250 assays for the detection of infectious agents using state of the art technology. In addition to the Molecular Diagnostics offerings, Clongen Laboratories has a licensed routine Microbiology laboratory for the culture and identification of bacteria, yeast and fungi.  

Recent changes to the company's website reflect changes to the organizational structure of the laboratory.  There are two sub-sites for the two business units, the Clinical Diagnostics Division and the Contract Research Division, which are physically and administratively separate.

The two business units perform distinct functions and can be seen at www.Clongen.com

Contact:  Ahmed Kilani, Ph.D., President and Laboratory Director at 301-916-0173 or e-mail akil@clongen.com  

SOURCE Clongen Laboratories

The MycoAlert kit utilizes a sensitive biochemical reaction that detects the activity of specific Mycoplasmal enzymes.  These enzymes catalyze the conversion of ADP to ATP.  The viable Mycoplasma are lysed and the enzymes react with the MycoAlert substrate producing a bioluminescent reaction that can be detected using a luminometer.  The following Bioluminescent reaction takes place and the signal is detected as Relative Light Units (RLUs):

The emitted light intensity is linearly related to the ATP concentration.  The reaction is performed at room temperature (18^o C – 22^o C).  The light emission is measured following a short incubation with the MycoAlert reagents and then another reading is taken following a short incubation with the MycoAlert substrate.  The ratio of the second reading to the first reading is used to determine whether the test is positive, negative or borderline. 

Turnaround Time:  24 hours from time of Sample receipt

Test Code:  131M

Sample type:  medium from cell culture, or medium with cells (cells should be maintained in antibiotic-free medium for 3-5 days for better results)

Cost: 

$99 per sample (1-10 samples in a shipment)

$89 per sample (10-20 samples in a shipment)

$79 per sample (20 or more)

Please complete the Biotech-Biopharm Sample submission form and send it along with the samples.

We are pleased to announce the release of our new website.  As we celebrate our seventh year in business, the rapid growth in both of the Clinical Diagnostics and Contract Research Divisions made it necessary to divide the lab. into two distinct areas and also separate the website to make information easily accessible to our clients who use the website as a portal for information.  The content of both sites will undergo constant updates over the next few months to keep you posted on our services, products and new offerings.   Thank you for your continued support and patronage.  We strive to offer the highest quality services and products.  By:  Ahmed Kilani, Ph.D. (President)

http://www.prnewswire.com/news-releases/clongen-laboratories-announces-formation-of-separate-clinical-diagnostics-and-contract-research-divisions-133891733.html

GERMANTOWN, Md., Nov. 15, 2011 /PRNewswire/ -- Since its inception in 1999, Clongen Laboratories, a CLIA licensed facility with a Maryland Clinical Laboratory license, has focused on improving human health by refining diagnostic tests for infectious diseases and providing contract research services for pharmaceutical, biotechnology, government, and academic institutions.

The advanced molecular diagnostics technology Clongen Laboratories uses in their Clinical Diagnostics Division offers a powerful tool in the screening of a wide range of infectious diseases. This allows healthcare practitioners to better diagnose and treat their patients.  One of the main areas of focus in the Clinical Diagnostics Division is tick borne illness testing; however, Clongen Laboratories also offers a large number of other assays, some not offered anywhere else in the US.  The technology platform Clongen Laboratories uses in the Clinical Diagnostics Division is Real Time PCR.  According to Ahmed Kilani, PhD, founder and director of Clongen Labs, this platform allows Clongen Laboratories to rapidly detect infectious agents in clinical samples at very low copy numbers.  The clinician receives laboratory test results in less than a week from the time of sample receipt.  This quick turnaround offers physicians the opportunity to manage clinical cases without delay.

Clongen Laboratories contract research services are performed under GLP and GMP conditions and encompass a wide range of assays available to pharmaceutical, biotechnology, government and academic institutions.  Services include sterility testing, Mycoplasma detection and elimination, Endotoxin testing and removal, and many others.  In recent years, due to the increased risk of bio-warfare agents, Clongen Laboratories developed rapid real time PCR based assays for the detection of all Bio-warfare select agents listed by the Centers for Disease Control and Prevention (CDC).  The contract research division has grown over the years and now covers a large number of established assays; many are required for lot release of biological and pharmaceutical products.  

The company has been enjoying steady growth and will soon obtain licensure in five additional states.  In addition, Clongen Laboratories is establishing satellite facilities in several other states. According to Dr. Kilani, the mission of Clongen Laboratories, which is to promote improved health through better diagnostic testing and research, has remained consistent since the laboratory was established.

Clongen Laboratories began with less than 10 assay offerings.  Today, the clinical diagnostics division offers more than 250 assays for the detection of infectious agents using state of the art technology. In addition to the Molecular Diagnostics offerings, Clongen Laboratories has a licensed routine Microbiology laboratory for the culture and identification of bacteria, yeast and fungi.  

Recent changes to the company's website reflect changes to the organizational structure of the laboratory.  There are two sub-sites for the two business units, the Clinical Diagnostics Division and the Contract Research Division, which are physically and administratively separate.

The two business units perform distinct functions and can be seen at www.Clongen.com

Contact:  Ahmed Kilani, Ph.D., President and Laboratory Director at 301-916-0173 or e-mail akil@clongen.com  

SOURCE Clongen Laboratories

 We offer a wide range of Microbiology services.  If you are trying to identify unknown contaminants, generate bacterial cell banks, study antibiotic resistance profiles, or you need to carry out a study described in a custom protocol or the USP manual, our Microbiology experts can definitely assist you.